Toggle navigation
Menu
Home
News
Local
National
World
Politics
Sports
Entertainment
Business
Health
News Tip Hotline
Weather
Bend
Traffic
Live Traffic Cams
Central Oregon
Mountain Passes
Road Reports
Trip Check
Gas Prices
Closures and Delays
Stations
KQAK-FM 105.7
The Peak 104.1
The Ranch 95.7 FM
KBNW-AM/FM
KRCO-AM
Events
Upcoming
Concerts
Submit An Event
Submit A PSA
Interviews
Inside Central Oregon
Central Oregon Spotlight
Water Wise Tips
HBG Interviews
Ray’s Random Questions
Just Used Cars as Heard on KQAK & The Ranch
About MCO
Contact/About Us
Advertise
Careers
Media Kit
Radio Stations
Contest Rules
Recent Quotes
View Full List
My Watchlist
Create Watchlist
Indicators
Industrial Estimate
Composite Estimate
500 Stocks Estimate
Gold
Crude Oil
Central Oregon Stock Index
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries
Articles published by Replimune Group Inc
Replimune Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
June 06, 2025
From
Replimune Group Inc
Via
GlobeNewswire
Tickers
REPL
Replimune Presents New Analyses from the IGNYTE Study of RP1 plus Nivolumab in Anti-PD1 Failed Melanoma at the 2025 American Society of Clinical Oncology (ASCO) Annual Meeting
June 01, 2025
From
Replimune Group Inc
Via
GlobeNewswire
Tickers
REPL
Replimune to Present at the 2025 Jefferies Global Healthcare Conference
May 29, 2025
From
Replimune Group Inc
Via
GlobeNewswire
Tickers
REPL
Replimune Reports Fiscal Fourth Quarter and Year End 2025 Financial Results and Provides Corporate Update
May 22, 2025
From
Replimune Group Inc
Via
GlobeNewswire
Tickers
REPL
Replimune Announces Dates for Fiscal Fourth Quarter and Year End 2025 Financial Results and Upcoming Investor Day
May 16, 2025
From
Replimune Group Inc
Via
GlobeNewswire
Tickers
REPL
Replimune Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
May 09, 2025
From
Replimune Group Inc
Via
GlobeNewswire
Tickers
REPL
Replimune Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
April 11, 2025
From
Replimune Group Inc
Via
GlobeNewswire
Tickers
REPL
Replimune Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
March 07, 2025
From
Replimune Group Inc
Via
GlobeNewswire
Tickers
REPL
Replimune Reports Fiscal Third Quarter 2025 Financial Results and Provides Corporate Update
February 12, 2025
From
Replimune Group Inc
Via
GlobeNewswire
Tickers
REPL
Replimune Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
February 07, 2025
From
Replimune Group Inc
Via
GlobeNewswire
Tickers
REPL
Replimune Announces Biologics License Application Acceptance and Priority Review for RP1 for the Treatment of Advanced Melanoma
January 21, 2025
From
Replimune Group Inc
Via
GlobeNewswire
Tickers
REPL
Replimune Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
January 10, 2025
From
Replimune Group Inc
Via
GlobeNewswire
Tickers
REPL
Replimune Announces RP2 Development Program Advances with First Patients Enrolled in Metastatic Uveal Melanoma and Hepatocellular Carcinoma Clinical Trials
January 08, 2025
From
Replimune Group Inc
Via
GlobeNewswire
Tickers
REPL
Replimune to Present at the 43rd Annual J.P. Morgan Healthcare Conference
December 23, 2024
From
Replimune Group Inc
Via
GlobeNewswire
Tickers
REPL
Replimune Announces Pricing of Upsized Public Offering
November 25, 2024
From
Replimune Group Inc
Via
GlobeNewswire
Tickers
REPL
Replimune Announces Proposed Public Offering
November 25, 2024
From
Replimune Group Inc
Via
GlobeNewswire
Tickers
REPL
Replimune Receives Breakthrough Therapy Designation for RP1 and Submits RP1 Biologics License Application to the FDA under the Accelerated Approval Pathway
November 21, 2024
From
Replimune Group Inc
Via
GlobeNewswire
Tickers
REPL
Replimune Reports Fiscal Second Quarter 2025 Financial Results and Provides Corporate Update
November 12, 2024
From
Replimune Group Inc
Via
GlobeNewswire
Tickers
REPL
Replimune Presents Late-Breaking Abstract Featuring Data from IGNYTE Clinical Trial of RP1 Combined with Nivolumab in Anti-PD1 Failed Melanoma at the 39th Annual Meeting of the Society for Immunotherapy of Cancer (SITC 2024)
November 09, 2024
From
Replimune Group Inc
Via
GlobeNewswire
Tickers
REPL
Replimune Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
November 08, 2024
From
Replimune Group Inc
Via
GlobeNewswire
Tickers
REPL
Replimune to Present at the 39th Annual Meeting of the Society for Immunotherapy of Cancer (SITC)
October 30, 2024
From
Replimune Group Inc
Via
GlobeNewswire
Tickers
REPL
Stock Quote API & Stock News API supplied by
www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the
Privacy Policy
and
Terms Of Service
.
© 2025 FinancialContent. All rights reserved.
581446795
Mozilla/5.0 (Windows NT 10.0; Win64; x64) AppleWebKit/537.36 (KHTML, like Gecko) Chrome/60.0.3112.113 Safari/537.36
00fbf3724072e3a4c643b60a8db5a8756c4f8c05
1
